netFormulary NHS
Demonstration Formulary
 Search
 Results

Looking for SMA found 78 matches

Formulary items 9 matches
Non-formulary items 8 matches
   
Open monograph to display formulary status BNF Category
  Fresh Frozen PlaSMA Cardiovascular system - Blood-related products - 02.11
  Beclometasone and formoterol  (Fostair®) Respiratory system - Corticosteroids - 03.02
  Beclometasone Dipropionate  (Clenil Modulite®) Respiratory system - Corticosteroids - 03.02
  Drug Delivery Device Respiratory system - Drug delivery devices - 03.01.05
  Fluticasone and salmeterol  (Seretide®)
(Inhaler) 		Respiratory system - Corticosteroids - 03.02
  Fluticasone propionate  (Flixotide®) Respiratory system - Corticosteroids - 03.02
  Low range peak flow meter Respiratory system - Peak flow meters - 03.01.05
  Salbutamol Respiratory system - Selective Beta2 agonists - 03.01.01.01
  Standard range peak flow meter Respiratory system - Peak flow meters - 03.01.05
 
Non Formulary BNF Category
  Fresh Frozen PlaSMA Cardiovascular system - Blood-related products - 02.11
  Mometasone  (ASMAnex®) Respiratory system - Corticosteroids - 03.02
  Tolcapone  (TaSMAr®) Central nervous system - Catachol-O-methyltransferase inhibitors - 04.09.01
  Beclometasone Dipropionate  (Kelhale® ) Respiratory system - Corticosteroids - 03.02
  Beclometasone Dipropionate  (Soprobec ®) Respiratory system - Corticosteroids - 03.02
  Drug Delivery Device Respiratory system - Drug delivery devices - 03.01.05
  Fluticasone and formoterol  (Flutiform®) Respiratory system - Corticosteroids - 03.02
  Salmeterol Respiratory system - Selective Beta2 agonists - 03.01.01.01


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (08.01.05)
link in drug section How to use a Metered Dose Inhaler with a Small Volume Spacer Device (03.02.03)
link in drug section How to use a Metered Dose Inhaler with a Small Volume Spacer Device (03.02.03)
link in drug section How to use a Metered Dose Inhaler with a Small Volume Spacer Device (03.02.03)
link in drug section HOw to use a Meterted Dose Inhaler with a Small Spacer (03.01.05)
link in drug section NICE TA124: Lung cancer (non-small-cell) - pemetrexed  (08.01.03)
link in drug section NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed (08.01.03)
link in drug section NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer (08.01.05)
link in drug section NICE TA184: Lung cancer (small-cell) - topotecan (08.01.05)
link in drug section NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer (08.01.05)
link in drug section NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)  (08.01.03)
link in drug section NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib  (08.01.05)
link in drug section NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (08.01.05)
link in drug section NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (08.01.05)
link in drug section NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (08.01.05)
link in drug section NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib  (08.01.05)
link in drug section NICE TA309: Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer (08.01.03)
link in drug section NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (03.11)
link in drug section NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (08.01.05)
link in drug section NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (08.01.05)
link in drug section NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (08.01.05)
link in drug section NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (08.01.03)
link in drug section NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (08.01.05)
link in drug section NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (08.01.05)
link in drug section NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (08.01.05)
link in drug section NICE TA428:Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (08.01.05)
link in drug section NICE TA447: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (08.01.05)
link in drug section NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer (08.02.03)
link in drug section NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer (08.02.03)
link in drug section NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer (08.01.05)
link in drug section NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (08.02.03)
link in drug section NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (08.01.05)
link in drug section NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (08.01.05)
link in drug section NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (08.01.05)
link in drug section NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (08.01.05)
link in drug section NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (08.01.05)
link in drug section NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (08.01.05)
link in drug section NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (08.02.03)
link in drug section NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (08.01.05)
link in drug section NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (08.01.05)
link in drug section NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (08.01.05)
link in drug section NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (08.02.03)
link in drug section NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (08.01.05)
link in drug section NICE TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (08.01.05)
link in drug section NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (08.01.05)
link in drug section NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (08.02.03)
link in drug section NICE TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura (09.01.04)
link in drug section NICE TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor (08.01.05)
link in drug section NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (08.01.05)
link in drug section NICE TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (09.01.03)
link in drug section NICE TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (08.02.03)
link in drug section NICE TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (08.01.05)
link in drug section NICE TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (08.02.03)
link in drug section NICE TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (08.02.03)
link in drug section NICE TA760: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (08.01.05)
link in drug section NICE TA761: Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (08.01.05)
link in drug section NICE TA770: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (08.01.05)
link in drug section NICE TA778: Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (08.01.05)
link in drug section NICE TA779: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (08.01.05)
link in drug section NICE TA781: Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (08.01.05)
link in drug section NICE TA789: Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (08.01.05)


 
netFormulary